ABSTRACT: Necrotising enterocolitis (NEC) causes significant morbidity and mortality in premature infants. The role of innate immunity in the pathogenesis of NEC remains unclear. Mannosebinding lectin (MBL) recognizes microorganisms and activates the complement system via MBL-associated serine protease-2 (MASP-2). The aim of this study was to investigate whether MBL and MASP-2 are associated with NEC. This observational case-control study included 32 infants with radiologically confirmed NEC and 64 controls. MBL and MASP-2 were measured in cord blood using ELISA. Multivariate logistic regression was performed. Of the 32 NEC cases (median gestational age, 30.5 wk), 13 (41%) were operated and 5 (16%) died. MASP-2 cord blood concentration ranged from undetectable (Ͻ10 ng/mL) to 277 ng/mL. Eighteen of 32 (56%) NEC cases had higher MASP-2 levels (Ն30 ng/mL) compared with 22 of 64 (34%) controls (univariate OR 2.46; 95% CI 1.03-5.85; p ϭ 0.043). Higher cord blood MASP-2 levels were significantly associated with an increased risk of NEC in multivariate analysis (OR 3.00; 95% CI 1.17-7.93; p ϭ 0.027). MBL levels were not associated with NEC (p ϭ 0.64). In conclusion, infants later developing NEC had significantly higher MASP-2 cord blood levels compared with controls. Higher MASP-2 may favor complement-mediated inflammation and could thereby predispose to NEC. A lthough prognosis for premature infants has improved over the last years as a result of advances in perinatal and intensive care, morbidity and mortality due to necrotising enterocolitis (NEC) remain high (1). Numerous risk factors, including prematurity, intrauterine growth retardation, formula feeding, bacterial infection, and intestinal ischemia have been implicated in the pathogenesis of the disease (2,3). However, since the exact pathophysiological mechanisms remain undefined, identification of infants at risk for NEC and early recognition of NEC represent a challenge (4).
A lthough prognosis for premature infants has improved over the last years as a result of advances in perinatal and intensive care, morbidity and mortality due to necrotising enterocolitis (NEC) remain high (1) . Numerous risk factors, including prematurity, intrauterine growth retardation, formula feeding, bacterial infection, and intestinal ischemia have been implicated in the pathogenesis of the disease (2, 3) . However, since the exact pathophysiological mechanisms remain undefined, identification of infants at risk for NEC and early recognition of NEC represent a challenge (4) .
Early infancy is a vulnerable period of transition from passive, transplacentally acquired immunity to individual, adaptive immunity. Since premature infants experience both humoral and cellular immunodeficiency, they rely on genetically determined innate defense mechanisms (5) . Innate immunity is mainly mediated by host proteins that recognize conserved pathogen-associated molecular patterns, such as repetitive sugar arrays present on many microorganisms but not on mammalian cells (6) . The lectin pathway of complement activation represents an important component of innate immunity and consists of Mannose-binding lectin (MBL) and L-and H-ficolins, which recognize various microorganisms (6) . Both MBL and ficolins rely on MBL-associated serine protease-2 (MASP-2) to activate the complement system (6) . Upon binding of MBL/MASP-2 complexes to microbial surfaces, MASP-2 sequentially cleaves C4 and C2, thereby generating the C3 convertase C4bC2b, which finally leads to opsonization and lysis of pathogens and recruitment of inflammatory cells (7) .
Due to single nucleotide polymorphisms within the MBL2 gene and the associated promotor region, MBL deficiency affects approximately 30% of the white population (6) . MBL deficiency has been associated with neonatal sepsis and pneumonia (8, 9) . Recently, a mutation has been identified in the MASP-2/MAp19 gene with a gene frequency of 1.3 to 6.3%, resulting in decreased MASP-2 serum concentrations in heterozygous individuals (10) . Although children with MASP-2 deficiency are prone to develop chemotherapy-related infections (11), the role of MASP-2 deficiency on susceptibility to infection in newborns remains unknown.
Since recent research indicates that the inflammatory reaction of the host may be crucial for the development of NEC (2, 3, 12) , we have hypothesized that the lectin pathway of complement activation may be involved in the pathogenesis of NEC. The aim of the present study was to investigate whether cord blood concentrations of MBL and MASP-2 are associated with later development of NEC.
PATIENTS AND METHODS
Infants born between April 2000 and August 2007 at the Department of Obstetrics and Gynecology, University of Bern, Switzerland, who developed NEC as defined by Bell stage II or III (13) were eligible for this study. Infants with major congenital malformations were excluded. The study was approved by the institutional review board including the fact that informed consent was not needed due to the retrospective nature of the study (Kantonale Ethikkommision, Direktion Forschung und Lehre, Inselspital, University of Bern, Bern, Switzerland). Treatment protocols of NEC and perinatal care of newborns did not substantially change during the study period.
Controls and matching criteria. For each patient, two matched controls were searched using the institutional neonatal database. Controls were matched for the following criteria since these were considered the main potential confounders (2,3): 1) gestational age (Ϯ1 wk); 2) small versus appropriate birth weight for gestational age (SGA: weight percentile Ͻ10); 3) prenatal maternal corticosteroid therapy for fetal lung maturation induction; 4) maternal chorioamnionitis, defined as maternal fever, elevated maternal C-reactive protein, fetal tachycardia, prolonged rupture of membranes and/or placental histology indicative of chorioamnionitis (14) ; and 5) perinatal asphyxia, defined as umbilical artery pH Ͻ7.10, umbilical artery base excess ՅϪ10 and Apgar score at 5 min Ͻ5 (15). Infants were not eligible as controls if they had suffered from significant abdominal disease such as suspicion of NEC during hospital stay or if they underwent abdominal surgery for any disease.
Outcome measures and data assessment. Occurrence of NEC was defined as primary outcome. Secondary outcomes included death attributed to NEC, time between birth and development of NEC, NEC requiring surgery (either primary or after failed conservative therapy), and Bell stage III (13) . Patient characteristics and clinical data were searched retrospectively using the institutional neonatal database and the patient charts.
MBL and MASP-2 measurements. Cord blood is routinely stored at our institution to determine Toxoplasma gondii serology in infants of mothers with unknown or negative serostatus. After centrifugation, cord blood serum was frozen in sterile tubes at Ϫ20°C. MBL and MASP-2 concentrations were measured using a commercially available ELISA (MBL oligomer ELISA kit by Antibodyshop, Gentofte, Denmark; MASP-2 HK326 ELISA kit by HyCult biotechnology, Uden, The Netherlands). According to the manufacturer, the MASP-2 assay is validated for values as low as 1.6 ng/mL. Due to the limited amount of cord blood serum available, a quantity of 40 uL was used at a dilution of 1:6 resulting in a MASP-2 detection limit of 10 ng/mL.
To compare the MASP-2 concentrations of this cohort with term neonates, blood was collected from 10 healthy term neonates at birth (cord blood) and at 1, 3, and 6 months.
Statistical analysis. Patients and controls were compared using uni-and multivariate logistic regression with NEC or severe NEC outcomes as dependent variable. The following variables were included as covariables in the multivariate model: all matching criteria (gestational age, intrauterine growth retardation, prenatal steroids, chorioamnionitis, perinatal asphyxia); variables that had shown a trend (p Ͻ 0.20) for association with NEC in univariate analyses (mode of delivery, birth weight); and previously described risk factors for NEC (sex, need for mechanical ventilation after birth, and persistent ductus arteriosus [PDA] requiring medical closure with indomethacine) (16 -19) . Spearman's rank correlation, Mann-Whitney U-test and Wilcoxon's rank sum test were used where appropriate.
According to previous studies, low MBL levels were defined as MBL cord blood concentrations Ͻ700 ng/mL (8, 9) . Contrary to MBL, no data exist on normal MASP-2 concentrations in neonates. Preliminary analysis showed that NEC patients had significantly more often MASP-2 concentrations above detection limit (10 ng/mL) than controls (19 . By means of receiver-operating-characteristics curve analysis, MASP-2 cord blood concentrations were categorized into lower MASP-2 levels (Ͻ30 ng/mL) and higher MASP-2 levels (Ն30 ng/mL). Several sensitivity analyses were performed based on different cut-offs for MBL and MASP-2.
Two-sided tests were used throughout, and p-values below 0.05 were considered significant. SPSS 13.0 software was used for all analyses.
RESULTS
During the study period, 8819 infants were born at the Department of Obstetrics and Gynecology, University of Bern, and 48 infants developed NEC. Sixteen (33%) children with NEC were excluded, because cord blood was unavailable. The remaining 32 infants with a median gestational age of 30.5 wk (range, 25-39) were enrolled as patients in the study. Baseline demographic data and presence of previously described risk factors for NEC were not significantly different between patients and controls (Table 1) . Infants developed NEC at a median age of 11 d (range, 1-51, IQR 6 to 19). Thirteen (41%) infants were operated and five (16%) died during hospital treatment as a direct consequence of NEC.
In the whole study population (patients and controls), MASP-2 cord blood concentrations ranged from undetectable (Ͻ10 ng/mL) to 277 ng/mL. Fifty-two of 96 (54%) infants had MASP-2 concentrations below detection limit. MASP-2 concentration was neither associated with gestational age (p ϭ 0.933) nor with any of the clinical parameters studied. MBL cord blood concentrations ranged from 29 to 4104 ng/mL with a median of 863 ng/mL and were positively correlated with gestational age and birth weight (p ϭ 0.024 and 0.014, respectively). The duration of storage did not significantly affect MBL or MASP-2 concentration (visual assessment and Spearman's rank correlation; data not shown) (20) . Median MASP-2 cord blood concentration was higher in NEC cases than in controls (median 38 ng/mL versus Ͻ10 ng/mL). Eighteen of 32 (56%) NEC cases versus 22 of 64 (34%) controls had higher MASP-2 cord blood levels (Ն30 ng/mL; univariate OR 2.46, 95% CI, 1.03-5.85, p ϭ 0.043) (Fig. 1) . Multivariate analysis adjusted for all matching criteria, sex, birth weight, mode of delivery, need for mechanical ventilation, and PDA, confirmed that infants developing NEC had significantly more often higher MASP-2 levels compared with controls (OR, 3.00; 95% CI, 1.17-7.93; p ϭ 0.027).
Sixteen of 32 (50%) NEC cases versus 26 of 64 (41%) controls had low MBL cord blood levels. No significant difference was found when comparing MBL levels between patients and controls (univariate OR, 1.46; 95% CI, 0.62-3.43; p ϭ 0.384; multivariate OR, 1.25; 95% CI, 0.49 -3.22; p ϭ 0.644). Several sensitivity analyses based on different cut-offs for MBL and MASP-2 were performed which confirmed the main results (data not shown).
None of the severe NEC outcomes, e.g. death, need for surgery or advanced Bell stage, was significantly associated with MBL or MASP-2 levels (data not shown). Infants with higher MASP-2 levels tended to develop NEC earlier than infants with lower MASP-2 levels (median 10.5 versus 15 d; p ϭ 0.323).
To explore the course of MASP-2 during infancy, we measured MASP-2 in 10 healthy term newborns in cord blood and over the first 6 mo of life. MASP-2 concentrations increased significantly during the first 6 mo (median at birth 128 ng/mL, at 6 mo 418 ng/mL; p ϭ 0.043), with the main rise occurring during the first 3 mo (p ϭ 0.018), see Figure 2 . MASP-2 cord blood concentrations in these term infants were significantly higher compared with premature infants (p ϭ 0.002).
DISCUSSION
The results of this case-control study indicate that higher MASP-2 cord blood levels are associated with a 3-fold increased risk to develop NEC. To the best of our knowledge, this is the first study investigating the role of the lectin pathway of complement activation in NEC.
Clinical studies on MASP-2 have reported an increased susceptibility to infection in MASP-2 deficient patients (11, 21) , whereas elevated MASP-2 levels were associated with a worse prognosis in adults with colorectal cancer, possibly by contributing to tumor-associated inflammation (22) . Recent studies have shown that MBL can aggravate reperfusion injury (24) and that the lectin pathway of complement activation can increase injury after intestinal ischemia (25) . Since MASP-2 represents the common pathway for both MBL and ficolins (7), higher MASP-2 levels in neonates may enhance complement activation after initial triggers, thereby generating potentially harmful inflammatory mediators such as C3a and C5a (26) and could thereby promote the development of NEC. The observed trend for infants with higher MASP-2 to develop NEC earlier than infants with lower MASP-2 is in line with this concept. Even if innate immunity plays a key role in the protection against invading organisms and in the establishment of the gut flora, its implication in NEC is poorly understood (3, 27) . The pathophysiological concept of NEC postulates that initially hypoperfusion and gastrointestinal immaturity lead to an increased vulnerability of the intestinal tract facilitating bacterial invasion (2, 3) . Research on the role of platelet activating factor and NFB in NEC models has demonstrated that the reaction of the host is decisive on whether NEC develops then (2, 3, 12) .
Overall MASP-2 cord blood concentrations in most neonates in our study were extremely low in comparison to values reported from adults and children (7, 11, 20, 22) . In a subset of healthy term infants, we were able to show that MASP-2 concentrations rise significantly during infancy approaching adult levels at the age of 6 mo (20) . Our results thus suggest that MASP-2 deficiency during the neonatal period is physiologic and that the lectin pathway of complement activation is not fully functional at birth in most premature infants. This novel finding has implications on the research on associated proteins, since both MBL and Ficolins rely on MASP-2 to activate complement. The finding of higher cord blood MASP-2 in infants later developing NEC in contrast to the extremely low MASP-2 concentrations found in most premature neonates suggests that MASP-2 deficiency may represent a protective mechanism against excessive proinflammatory stimuli during the neonatal period.
No association was found between cord blood MBL and NEC. The concentrations of MBL measured in our cohort were in good agreement with published results and correlated with gestational age, as reported previously (8, 9) . Several authors have reported increased frequency of neonatal sepsis and pneumonia in MBL deficient neonates (8, 9) , whereas two studies which were based on MBL genotype could not confirm this finding (28, 29) . The protective role of MBL and MASP-2 found in studies focusing on sepsis, which is usually caused by a single pathogen, apparently does not apply to multifactorial NEC.
The strengths of this study include the detailed matching aimed at minimizing potential confounders (3, 16, 17) . A relevant bias due to acute-phase reactions in cord blood measurements is unlikely, since we carefully matched infants for perinatal factors that may affect the hepatic synthesis of MBL and MASP-2. Comparison of nonmatched perinatal characteristics revealed no significant differences between patients and controls. Since data on normal MASP-2 concentrations in the neonatal period are lacking, receiver-operating-characteristics curve analysis was used to define MASP-2 levels. Although we have not determined MASP-2 concentrations during NEC, we assume that cord blood concentrations influence MASP-2 levels during the first weeks of life when NEC usually develops, similar to MBL (8, 31) . In addition, determining MASP-2 in cord blood has the advantage of obtaining baseline values that are independent from acute-phase reactions associated with NEC itself.
This study has some limitations, mostly related to its retrospective design. Thirty-three percent of infants who developed NEC during the study period were excluded because cord blood serum was unavailable. A selection bias, however, seems unlikely, since the clinical characteristics of the patients included are in good agreement with a larger NEC cohort recently described (4). Similar to most studies on NEC (3, (32) (33) (34) , sample size is a major limitation when interpreting results particularly with regard to secondary NEC outcomes.
In conclusion, we report that higher cord blood MASP-2 levels were significantly associated with a 3-fold increased risk to develop NEC. Although independent replication by other cohorts is needed, our results suggest that higher MASP-2 may represent a previously unrecognized risk factor for NEC. Whether determination of MASP-2 may help to identify infants at increased risk of NEC and to improve early recognition of NEC needs to be assessed in future prospective studies. In contrast, the novel finding of extremely low MASP-2 concentrations in most premature infants compared with the values reported from older children suggests that the lectin pathway of complement activation is often not fully functional at birth. Further studies should therefore address the role and maturation of the lectin pathway of complement activation, including ficolins, in the neonatal period.
